First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).

被引：3
|
作者：
von Tresckow, Bastian
Gundermann, Stefan
Eichenauer, Dennis A.
Aulitzky, Walter Erich
Goebeler, Mariele
Sayehli, Cyrus
Bacchus, Liza
Hauns, Bernhard
Mais, Anna
Hentsch, Bernd
Kohihof, Hella
Krauss, Rolf
Krauss, Babett
Baumgartner, Roland
Vitt, Daniel
Engert, Andreas
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, D-97070 Cologne, Germany
[2] Univ Hosp Wuerzburg, Wurzburg, Germany
[3] Robert Bosch Klin, Stuttgart, Germany
[4] Univ Wurzburg, Med Ctr, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[5] Robert Bosch Krankenhaus, Stuttgart, Germany
[6] 4SC AG, Planegg Martinsried, Germany
[7] Novartis, Basel, Switzerland
[8] 4SC, Planegg Martinsried, Germany
[9] 4SC AG, Martinsried, Germany
[10] Univ Hosp Cologne, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8559
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY)
    von Tresckow, B.
    Goebeler, M. E.
    Sayehli, C.
    Gundermann, S.
    Eichenauer, D.
    Aulitzky, W.
    Bacchus, L.
    Igel, S.
    Schwab, M.
    Sasse, S.
    Hauns, B.
    Mais, A.
    Hentsch, B.
    Kohlhof, H.
    Krauss, R.
    Krauss, B.
    Baumgartner, R.
    Vitt, D.
    Engert, A.
    HAEMATOLOGICA, 2014, 99 : 711 - 711
  • [2] Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor
    Henning, S. W.
    Doblhofer, R.
    Kohlhof, H.
    Jankowsky, R.
    Maier, T.
    Beckers, T.
    Schmidt, M.
    Hentsch, B.
    EJC SUPPLEMENTS, 2010, 8 (07): : 61 - 61
  • [3] Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
    von Tresckow, Bastian
    Sayehli, Cyrus
    Aulitzky, Walter E.
    Goebeler, Maria-Elisabeth
    Schwab, Matthias
    Braz, Eunice
    Krauss, Babett
    Krauss, Rolf
    Hermann, Frank
    Bartz, Rene
    Engert, Andreas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (02) : 163 - 173
  • [4] A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors
    Brunetto, A. T.
    Ang, J. E.
    Lal, R.
    Olmos, D.
    Frentzas, S.
    Mais, A.
    Hauns, B.
    Mollenhauer, M.
    Lahu, G.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
    Maria Pinkerneil
    Michèle J. Hoffmann
    Hella Kohlhof
    Wolfgang A. Schulz
    Günter Niegisch
    Targeted Oncology, 2016, 11 : 783 - 798
  • [6] Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
    Pinkerneil, Maria
    Hoffmann, Michele J.
    Kohlhof, Hella
    Schulz, Wolfgang A.
    Niegisch, Guenter
    TARGETED ONCOLOGY, 2016, 11 (06) : 783 - 798
  • [7] Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells
    Huang Zhijun
    Wang Shusheng
    Min Han
    Li Jianping
    Qin Li-sen
    Li Dechun
    TUMOR BIOLOGY, 2016, 37 (08) : 10257 - 10267
  • [8] Antitumor effects of an epigenetic inhibitor, 4SC-202, on human osteosarcoma cells
    Torres, Haydee Magdalena
    Van Cleave, Ashley
    Palmer, Mykayla
    Callahan, Dakota
    Smithback, Austyn
    May, Danielle
    Roux, Kyle
    Tao, Jianning
    CANCER RESEARCH, 2020, 80 (16)
  • [9] A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
    Kumar, Shaji
    Kapoor, Prashant
    Alencar, Alvaro
    Murthy, Guru Subramanian Guru
    Hoffmann, Marc
    Pagel, John
    Patel, Vishalkumar
    Pauff, James
    Zinzani, Pier Luigi
    Le Gouill, Steven
    Mato, Anthony R.
    Jurczak, Wojciech
    Roeker, Lindsey E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S37 - S38
  • [10] A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress).
    Roeker, Lindsey Elizabeth
    Alencar, Alvaro Jose
    Murthy, Guru Subramanian Guru
    Hoffmann, Marc Steven
    Pagel, John M.
    Patel, Vishalkumar
    Pauff, James Michael
    Zinzani, Pier Luigi
    Le Gouill, Steven
    Mato, Anthony
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345